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Abstract
Background: Mycobacterium tuberculosis drug resistance is a major challenge to the use of standardized regimens
for tuberculosis (TB) therapy, especially among previously treated patients. We aimed to investigate the frequency
and pattern of drug resistance among previously treated patients with smear-positive pulmonary tuberculosis at the
Korle-Bu Teaching Hospital Chest Clinic, Accra.
Methods: This was a cross-sectional survey of mycobacterial isolates from previously treated patients referred to
the Chest Clinic Laboratory between October 2010 and October 2013. The Bactec MGIT 960 system for mycobactrerial
culture and drug sensitivity testing (DST) was used for sputum culture of AFB smear-positive patients with
relapse, treatment failure, failure of smear conversion, or default. Descriptive statistics were used to summarize
patient characteristics, and frequency and patterns of drug resistance.
Results: A total of 112 isolates were studied out of 155 from previously treated patients. Twenty contaminated (12.9%)
and 23 non-viable isolates (14.8%) were excluded. Of the 112 studied isolates, 53 (47.3%) were pan-sensitive to all first-line
drugs tested Any resistance (mono and poly resistance) to isoniazid was found in 44 isolates (39.3%) and any resistance to
streptomycin in 43 (38.4%). Thirty-one (27.7%) were MDR-TB. Eleven (35.5%) out of 31 MDR-TB isolates were
pre-XDR. MDR-TB isolates were more likely than non-MDR isolates to have streptomycin and ethambutol resistance.
Conclusions: The main findings of this study were the high prevalence of MDR-TB and streptomycin resistance among
previously treated TB patients, as well as a high prevalence of pre-XDR-TB among the MDR-TB patients, which
suggest that first-line and second-line DST is essential to aid the design of effective regimens for these groups of
patients in Ghana.
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Background
The use of standardized regimens for previously treated
tuberculosis (TB) patients is a concern as inadequate
therapy in the presence of pre-existing Mycobacterium
tuberculosis drug resistance could lead to amplification
and spread of resistance through selective pressure, increas-
ing the risk of multi-drug resistant (MDR), and extensively
drug resistant (XDR) tuberculosis [1–3]. Previously treated
TB patients in areas where drug susceptibility testing (DST)
is not routinely available who fail or relapse on the first-line
regimen (isoniazid [H], rifampicin [R], pyrazinamide
[Z], and ethambutol [E]) are given an empiric standard-
ized retreatment regimen consisting of 2 months of HRZE
plus streptomycin (S), 1 month of HRZE and 5 months
HRE (2SHRZE/1HRZE/5HRE), still using first-line drugs as
per current WHO guidelines [4]. Studies in other African
and low-income countries have shown that there is cause
for concern as treatment outcomes of the retreatment regi-
men show success rates of only 50–60%, worse in Category
I treatment failures and smear positive patients who have
relapsed [5–7]. A recent study in Uganda looking at long
term mortality in patients following the retreatment regi-
men, with a median follow up interval of 3 years, found
majority (62%) of patients had died, and some of the living
still had active smear positive TB [8].
Patients with MDR-TB in Ghana, like in other TB en-
demic areas where DST for second-line drugs is not avail-
able, are prescribed a standardized treatment regimen. In
2015 a national review of the standardized MDR-TB
regimen made capreomycin (Cm) the preferred choice
of ‘injectable’ because of concern about increased renal
complications with kanamycin (Km). Prior to this they
were given kanamycin, except for patients over 60 years
old or those at risk of impaired kidney function who
were given capreomycin. Levofloxacin (Lfx) is the usual
choice of fluoroquinolone as it is less expensive, but pa-
tients would rarely be switched to moxifloxacin if during
treatment they showed signs of new onset or worsening
kidney failure. Other drugs include prothionamide (Pto),
cycloserine (Cs), and pyrazinamide (Z), with ethambutol
added when first-line DST showed sensitivity of the organ-
ism to ethambutol [9]. The current national guidelines
recommend an 8 month intensive phase regimen of Z-
Cm(Km*)-Lfx-Pto-Cs(PAS*) and 12 months of Z-Lfx-Pto-
Cs (PAS*), with kanamycin (Km*) and para-amino salicylic
acid (PAS*) as alternatives to capreomycin and cycloserine
respectively.
Whether these standardized regimens are appropriate
is unknown and has not been studied in this country.
The aim of this study was to investigate the frequency
and patterns of Mycobacterium tuberculosis drug re-
sistance in previously treated TB patients, to inform
appropriate drug regimen selection in this group of
patients.
Methods
We carried out a cross-sectional study of previously
treated patients (patients with relapse, treatment failure,
failure of smear conversion, or default), who had acid-
fast bacilli (AFB) smear-positive pulmonary TB and were
referred to the KBTH Chest Clinic Laboratory for cultures
between October 2010 and October 2013. Majority of
these (84%) had been on Category I treatment only. At the
time of the study, the Chest Clinic did not routinely cul-
ture the sputum of all previously treated pulmonary TB
patients who had failed, relapsed or defaulted treatment.
The Chest Clinic laboratory, being one of two national TB
culture laboratories, receives sputum samples from treat-
ment failure and relapse patients mostly in Greater Accra
region, with few from other regions in southern Ghana. In
addition, for this study we included the culture of patients
who failed to convert to sputum smear negative at month
2 of the standard (Category I) regimen.
Mycobacterial culture of sputum samples was performed
using the Bactec MGIT 960 system and Mycobacterium
tuberculosis isolates confirmed by colony morphology, and
with a MGIT MTBcID kit®. Isolates were prepared and
stored in Tryptone soya broth with glycerol at -20 °C, until
shipment on dry ice to the Bacteriology P3 Laboratory in
the Medical Research Council (MRC), the Gambia. There
samples were re-cultured and first-line DST performed for
isoniazid, rifampicin, ethambutol and streptomycin, accord-
ing to the manufacturer’s instructions for BACTEC MGIT
960 [10]. DST to pyrazinamide was not done as it is
not required for routine clinical practice. MDR-TB iso-
lates were subjected to second-line drug DST using the
following drugs and cutoffs: capreomycin (2.5 μg/mL),
kanamycin (5 μg/mL), ofloxacin (2 μg/mL), and ethion-
amide (5 μg/mL) (Sigma-Aldrich, St. Louis, Mo, USA)
[11]. Descriptive statistics were used to summarize patient
characteristics, frequency and pattern of drug resistance.
Differences between patients with MDR and non-MDR
TB were compared using Systat version 13.0 (Systat
Software, Inc. San Jose, CA).
Results
There were 177 Mycobacterium tuberculosis isolates
shipped to the MRC, Gambia, of which 155 were from
previously treated patients, the rest being newly diag-
nosed smear positive tuberculosis. Of the 155 study iso-
lates from previously treated patients, 23 (14.8%) were
non-viable and 20 (12.9%) contaminated isolates were
excluded. The final study population consisted of 112
previously-treated patients for whom phenotypic DST
data was generated. The patient features of the 43 ex-
cluded isolates did not differ significantly from those of
the isolates studied, with a mean age of 39.3 years in the
study group and 46.8 years in those excluded and males
forming 75.9% and 83.7% respectively. The breakdown of
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the patients included in the study and those excluded by
prior treatment status is shown in Table 1. There was no
significant difference between them. Of the 112 patients
studied the majority (71.4%) were presenting for the start
of Category II (retreatment) regimen after treatment fail-
ure or relapse from a prior Category I treatment, while 10
on Category I treatment (8.9%) had failed to convert to
smear negative after 2 months or after 1 month (in two
cases). Fourteen (12.5%) had failed or relapsed on Cat-
egory II at 5 months, and treatment classification data was
missing for 7 patients. There were very few due to loss to
follow-up (default) (Table 1).
Overall, 53 (47.3%) were susceptible to all the first-line
drugs tested. Six isolates (5.4%) were pan-resistant. Any
resistance to isoniazid, streptomycin, rifampicin and eth-
ambutol was observed in 39.3%, 38.4%, 30.4% and 7.1%
of the patients, respectively (Table 2). Thirty-one (27.7%)
of the 112 isolates in the study were MDR.
The MDR-TB patients were significantly more likely
than those with non-MDR isolates to have streptomycin
and ethambutol resistance, 74.2% and 22.6% respectively
in MDR isolates compared with 24.7% and 1.2% in non
MDR-TB (Table 3). Pre-extensively drug resistant (Pre-
XDR) TB was found in 11 of the 31 isolates (35.5%), re-
sistant to either ofloxacin (8 patients) or capreomycin (3
patients). One MDR isolate was resistant to both capreo-
mycin and kanamycin, and 10 (32.3%) were resistant to
ethionamide (Table 2). There were no cases of XDR-TB
identified in our study population.
Discussion
The main findings of this study are the high prevalence
of streptomycin resistance and MDR-TB among previ-
ously treated TB patients, as well as a high prevalence of
pre-XDR-TB among the MDR-TB patients. In our study
28% of the patients had MDR-TB. In addition, 36% of
the MDR-TB patients had resistance to either a quin-
olone or second-line aminoglycoside (pre-XDR TB), and
would have a suboptimal response to the standardized
MDR-TB regimen given to all patients with MDR.
The frequency of MDR-TB in the current study is
similar to the 24% reported in a previous study in Ghana
that evaluated 17 patients [9], but it is lower than the
36% that we reported among 28 chronic smear-positive
pulmonary TB cases who had failed one to three super-
vised retreatment regimen [12]. The higher rate that we
previously observed among the chronic cases may be due
to the repeated use of the Category II regimen in patients
who had failed or relapsed on a previous retreatment since
MDR-TB could not be diagnosed at a time when DST was
Table 1 Previous first-line antituberculosis treatment status
among previously treated tuberculosis patients at the Korle-Bu
Teaching Hospital Chest Clinic, Accra
Treatment status In study
(N = 112*)
Excluded
(N = 43)
Prior Cat I therapy
Failure or Relapse after prior therapy 80 (71.4%) 35 (81.4%)
Default of prior therapy 1 (0.9%) 2 (4.5%)
AFB smear-positive after 2 months of therapy 8 (7.1%) 2 (4.5%)
Smear-positive after 1 month of therapy 2 (1.8%) 0 (0.0%)
Prior Cat II therapy
AFB smear-positive after 5 months of therapy 14 (13.3%) 4 (9.1%)
*Treatment classification data was missing for 7 patients
Table 2 Pattern of drug resistance among previously treated
tuberculosis patients at the Korle-Bu Teaching Hospital Chest
Clinic, Accra
Characteristic Number Percent
First-line drug resistance (n = 112)
Pan-sensitive 53 47.3%
Any resistance
S 43 38.4%
H 44 39.3%
R 34 30.4%
E 8 7.1%
Mono resistance
S 12 10.7%
H 6 5.4%
R 1 0.9%
E 0 0.0%
Poly resistance/Other
HS 6 5.4%
RS 2 1.8%
HE 1 0.9%
(HR) MDR TB 31 27.7%
MDR TB (n = 31)
HR only 7 6.3%
HRS 17 15.2%
HRE 1 0.9%
HRES 6 5.4%
Second-line drug resistance (n = 31)
Pre-XDR TBa 11 35.5%
Ofloxacin 3 9.7%
Capreomycin 8 25.8%
Kanamycin 1b 3.2%
Ethionamide 10 32.3%
S streptomycin, H isoniazid, R rifampin, E ethambutol, MDR-TB multidrug
resistant tuberculosis, pre-XDR pre-extensively drug resistant tuberculosis
aPre-XDR TB is resistance to either a second-line injectable (kanamycin,
capreomycin) or a fluoroquinolone (ofloxacin), but not both
bone patient had resistance to both capreomycin and kanamycin, but
not ofloxacin
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not available at our center. Other studies from the West
African region, one in Cameroon [13], and another in
Nigeria [14] reported MDR-TB prevalence among smear
positive previously treated patients of 12% and 19%, re-
spectively. These rates are lower than the rates of the 24
to 36% in the Ghanaian studies [9, 12]. In contrast a study
in Burkina Faso reported the frequency of MDR-TB to be
50.5% among previously treated patients [15]. These vari-
able trends between countries in the West African region
underscore the need for each country to carefully examine
their local epidemic and tailor national treatment guide-
lines to the local situation. It is yet to be determined if the
standardized regimen for MDR-TB in Ghana is effective.
This study confirms the high prevalence of streptomycin
resistance among previously treated TB patients in Ghana
as reported in other Ghanaian studies [9, 12]. An explan-
ation for the high levels of streptomycin resistance could
be because of the many years of streptomycin use for
first-line treatment up until 2005–2007, when etham-
butol gradually replaced streptomycin in the standard
regimen. Some streptomycin resistance could also have
resulted from reactivation of latent TB infection resulting
from transmission of primary streptomycin resistance
present in the community. A large survey across Ghana of
2064 new smear positive cases from 2001 to 2004 found
that 17% of cases had streptomycin resistance [16].
The continuing use of streptomycin for Category II
regimens since the study in the early 2000’s might have
amplified the presence of streptomycin resistance, as in
our previous study which found 80% streptomycin resist-
ance among previously treated chronic TB patients [9, 12].
These findings suggest that the high level of streptomycin
resistance presently among previously treated patients in
Ghana will render ineffective the standardized Category II
regimen that adds only streptomycin to the first-line ther-
apy. A study by Nakanwagi-Mukwaya and colleagues in
Uganda have shown that while only 32% of previously
treated patients received Category II treatment there were
no differences in outcome with those on Category I [5]. An-
other study in Peru found 20% resistance to streptomycin
and found outcomes were better with Category I than
Category II treatment, in support of the phasing out of
Category II treatment in Peru [17]. Additionally in
Thailand, patients with rifampicin resistance or MDR-
TB who had received Category II treatment were found
to have poorer outcomes [18].
In Ghana about 15,000 patients are diagnosed with TB
annually, and the number of previously treated patients
presenting for retreatment make up 5–6% of all TB
patients diagnosed. In a review of national TB control
programme (NTP) data on previously treated patients in
2015, 46% were relapse patients, 26% had defaulted or
failed treatment, and 27% were grouped together and in-
cluded extrapulmonary TB, smear negative pulmonary
TB, and patients who were unable to do a sputum smear.
There was an average treatment success rate of 77% across
all categories of previously treated patients, and a mean
mortality of 11%. At the Korle Bu Teaching Hospital
(KBTH) 216 previously treated smear positive patients,
registered from January 2010 to June 2015, were found to
have a low treatment success rate of 59%, and 17% who
relapsed/failed treatment (T. Bouton, A. Forson unpub-
lished data). Other outcomes were 11% transferred out (to
other centres), while default was 4%. NTP data from 2015
(Table 4) showed differences between the regions, with
Ashanti and Western Regions having the highest numbers
of previously treated TB patients, yet with the highest
treatment success rates (85–90%), and Greater Accra Re-
gion which had treatment success rates of 80%. However,
the two largest teaching hospitals in the southern sector
(Korle Bu Teaching Hospital in Accra) and the northern
sector (Komfo Anokye Teaching Hospital in Ashanti) had
Table 3 Comparison of frequency of additional drug resistance
in MDR and non-MDR TB patients at the Korle-Bu Teaching
Hospital Chest Clinic, Accra
Characteristic Non-MDR-TB
(N = 81)
MDR-TB
(N = 31)
P value
Streptomycin resistance < 0.001
Yes 20 (24.7%) 23 (74.2%)
No 61 (75.3%) 8 (25.8%)
Ethambutol resistance < 0.001
Yes 1 (1.2%) 7 (22.6%)
No 80 (98.8%) 24 (77.4%)
MDR-TB multidrug resistant tuberculosis
Table 4 Summary of previously treated TB patients in Ghana in
2015, by region
Region Relapse Failure Default Other TOTAL
ASHANTI 110 21 26 26 183
WESTERN 55 10 22 22 109
CENTRAL 42 7 10 10 69
EASTERN 43 12 16 16 87
G-ACCRA 54 13 18 18 103
NORTHERN 10 9 5 5 29
U-EAST 17 16 5 5 43
U-WEST 11 7 3 3 24
VOLTA 22 14 8 8 52
BARa 55 15 6 6 82
KATHa 10 0 2 2 14
KBTHa 13 3 6 6 28
TTHa 3 0 0 0 3
Grand Total 445 127 127 268 967
aBAR Brong Ahafo Region, KATH Komfo Anokye Teaching Hospital
KBTH Korle-Bu Teaching Hospital, TTH Tamale Teaching Hospital
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the poorest outcomes, with mortality rates of 35% and
42% respectively. High mortalities are the main reason for
low success rates in these two facilities, which provide in-
patient care for the more severely ill patients.
Similar drug resistance surveillance studies are necessary
in other regions, particularly in the Northern sector, as this
study’s findings cannot be said to be representative of the
whole of Ghana. TB treatment outcomes in the country to
a large extent depend on drug sensitivity patterns in the
region, as well as the effectiveness of DOTS supervision
and monitoring. Differences between the regions may exist,
as in the Ashanti region (in the Northern half of Ghana)
where in spite of high treatment relapse/failure patient
numbers they had one of the highest retreatment success
rates (85.0%) on the Category II regimen. Using the tertiary
hospital in this study, providing care for the more severely
ill patients, could have predisposed to the selection for cul-
ture of the more resistant isolates, which would be expected
to be the cause of more severe disease.
In the current study, 36% of the MDR-TB isolates
were pre-XDR. A previous study that included only 17
previously-treated cases, identified that two (12%) of
the MDR-TB cases were pre-XDR [9]. The presence of
pre-XDR-TB in patients that are naïve to second-line
therapy in the current and the prior Ghana studies is
surprising, and could be related to antimicrobial resistance
(ciprofloxacin, gentamycin, amikacin) as a result of the
frequent use of these for other infectious diseases [19].
Conclusion
Overall, our findings suggest that first-line and second-line
DST is essential to aid the design of effective regimens for
these groups of patients in Ghana. The present study un-
derscores the need for a scale up of routine DST in previ-
ously treated TB patients and the use of effective regimens
based on susceptibility test results, in order to avoid the
emergence of XDR-TB in Ghana. This situation is not
unique to Ghana. Ongoing use of standardized regimens
for previously treated TB patients without DST guidance
may lead to amplification and transmission of resistant TB.
Limitations of our study include the fact that our sample
size was small and was not representative of the whole
country. Our study represented mainly the region of the
capital, Greater Accra, and regions in the southern part of
Ghana, and precludes generalization to the rest of Ghana.
Another limitation of this study was that only previously
treated TB patients with a positive sputum smear sample
were selected, as routine culture of all previously treated
patients was not available at the time of the study. Cur-
rently, all previously treated tuberculosis patients have
sputum cultures done, so there is the need in subsequent
studies to include all culture positive patients. Further
studies and review of nationwide drug resistance surveil-
lance data will be necessary.
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